VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LAB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LABStandard BioTools Inc.
$0.54$223M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLABCash Flow

Standard BioTools Inc. (LAB) Cash Flow Statement

20Y historyFree accessUpdated daily

Operating cash flow was -$6.2M in 2026Q3 after a -$56.9M outflow in 2026Q2, suggesting the burn narrowed but working capital swings of -$54.9M in 2026Q1 indicate cash conversion remains unreliable.

Income StatementBalance SheetCash FlowRatios

LAB Cash Flow Statement

Annual statement

LAB Cash Flow Statement

Standard BioTools Inc. (LAB) cash flow statement — 20-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06
Cash from Operations-64.27M-74.35M-143.45M-43.29M-89.37M-44.06M-15.42M-35.21M-25.2M-24.1M-39.1M-34.7M-22.62M-1.59M-17.48M-17.54M-11.51M-19.51M-28.72M-21.76M-22.31M
Operating CF Margin %--87.13%-82.24%-40.71%-91.24%-33.74%-11.16%-30.03%-22.31%-23.64%-37.43%-30.25%-19.43%-2.24%-33.4%-40.92%-34.29%-76.79%-187.14%-299.09%-348.64%
Operating CF Growth %159.98%48.17%-231.4%51.56%-102.83%-185.79%56.21%-39.72%-4.58%38.37%-12.69%-53.37%-1321.94%90.9%0.36%-52.43%41.02%32.06%-31.99%2.45%-
Net Income-39.21M-74.9M-138.88M-74.66M-190.1M-59.24M-53.02M-64.79M-59.01M-60.53M-75.98M-53.31M-52.83M-15.82M-19.02M-22.47M-16.9M-19.13M-29.5M-25.45M-23.55M
Depreciation & Amortization6.44M10.98M16.86M15.18M15.03M15.57M15.92M15.8M16.57M18.61M17.94M16.11M4.06M2.55M1.48M1.06M1.5M1.94M1.97M2.14M1.46M
Stock-Based Compensation22.34M29.61M31.73M13.12M14.88M16.1M14.45M11.39M11.02M9.09M13.86M16.83M20.94M6.44M4.09M2.8M1.59M2.11M2.02M708K145K
Deferred Taxes000000212K0141K00-2.33M-332K-1.78M023.37M-10K-1.9M14K00
Other Non-Cash Items-191.46M4.93M-41.08M1.28M83.17M1.51M4.6M18.89M8.55M-468K339K-3.76M13.39M296K78K-21.31M445K135K-769K335K846K
Working Capital Changes-34.66M-44.98M-12.08M1.79M-12.35M-18.01M2.41M-16.51M-2.48M9.2M4.75M-8.23M-7.85M6.72M-4.1M-990K1.87M-2.67M-2.46M511K-1.2M
Change in Receivables8.77M-1.36M8.97M-2.99M1.06M6.73M-7.63M-2.08M-1.79M-554K10.52M-2.76M-3.39M2.41M-3.7M-1.22M209K-4M-3.28M-135K-400K
Change in Inventory1.68M-11.52M-9.88M-4.91M-8.47M-4.78M-8.64M-3.05M1.49M4.6M-3.39M-3.74M-6.16M-1.53M-1.68M-1.08M-961K1.51M-20K-2.46M-955K
Change in Payables-4.87M2.44M01.62M003.36M0-294K585K-2.27M769K107K1.8M-1.81M540K932K-637K135K1.54M-575K
Cash from Investing199.65M24.77M363.17M20.24M-88.13M-11.95M39.98M-39.3M4.72M17.66M45.1M25.74M-178.38M-27.57M14M-45.11M-1.33M-688K6M-6.74M-2.94M
Capital Expenditures-1.39M-8.3M-8.36M-2.83M-3.83M-13.26M-12.72M-2.53M-372K-1.62M-5.07M-10.65M-7.4M-4.69M-2.38M-1.68M-1.54M-799K-910K-973K-2.93M
CapEx % of Revenue1.65%9.73%4.79%2.66%3.91%10.16%9.21%2.16%0.33%1.59%4.85%9.29%6.36%6.58%4.56%3.91%4.59%3.14%5.93%13.37%45.83%
Acquisitions22.49M0278.65M000-5.15M0050K2.33M-2.33M-112.86M3.12M-14M000000
Investments---------------------
Other Investing386.3M-5M92.88M0-84.3M1.32M21.04M-36.77M5.09M-50K50.17M2.33M-57.79M-24.12M14M-2.02M206K111K625K19K-8K
Cash from Financing-156K570K-102.62M-6.81M230.76M15.96M20.86M2.79M57.66M29M76K5.3M200.33M5.81M48.52M70.37M3.8M16.94M6.33M37.55M31.12M
Debt Issued (Net)00-63.19M-2.08M18.16M9.5M03.17M0000195.21M0-10.19M-7.87M3.13M9.48M6.14M1.5M9M
Equity Issued (Net)346K1.05M-40.95M-5.55M-774K-1.79M20.23M-629K59.47M28.79M-111K05.11M056.01M76.95M633K7.41M035.91M21.93M
Dividends Paid000000000000000000000
Share Repurchases-598K0-40.95M-5.41M-774K-1.79M0-629K00-111K-151K00000000-69K
Other Financing-502K-484K1.52M827K213.37M8.25M631K245K-1.81M204K187K5.3M05.81M2.7M1.29M39K53K180K147K190K
Net Change in Cash134.91M-48.17M116.32M-29.82M52.86M-40.07M45.8M-71.67M37.34M23.01M5.93M-4.6M-1.55M-23.39M45.1M7.83M-8.88M-3.19M-16.28M9.06M5.86M
Free Cash Flow-65.66M-82.65M-151.81M-46.12M-93.19M-57.33M-28.13M-37.74M-25.57M-25.71M-44.16M-45.35M-30.03M-6.28M-19.86M-19.22M-13.05M-20.31M-29.63M-22.73M-25.24M
FCF Margin %-77.76%-96.86%-87.03%-43.37%-95.15%-43.9%-20.37%-32.19%-22.64%-25.23%-42.28%-39.53%-25.78%-8.82%-37.95%-44.83%-38.88%-79.93%-193.07%-312.47%-394.47%
FCF Growth %33.29%45.55%-229.18%50.51%-62.57%-103.76%25.46%-47.58%0.55%41.77%2.61%-51.03%-378.35%68.4%-3.35%-47.3%35.77%31.45%-30.34%9.93%-
FCF per Share-0.17-0.22-0.43-0.58-1.19-0.76-0.39-0.57-0.64-0.78-1.52-1.58-1.08-0.25-0.90-1.08-0.69-11.70-17.92-12.03-13.35
FCF Conversion (FCF/Net Income)1.67x0.99x1.03x0.58x0.47x0.74x0.29x0.54x0.43x0.40x0.51x0.65x0.43x0.10x0.92x0.78x0.68x1.02x0.97x0.85x0.95x
Interest Paid8K15K3.09M3.82M3.49M3.15M3.09M3.54M5.53M5.53M5.53M5.54M2.75M7K579K1.72M00000
Taxes Paid1.02M00801K00521K0321K245K355K189K187K242K181K42K00000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Persistent operating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Earnings Repeatedly Diverge From Operating Cash

As reported in the quarterly cash flow statements, LAB's operating cash flow was negative in most of the ten quarters, while net income swung widely and turned positive in 2026Q3 at $13.5M against operating cash outflow of -$6.2M.

The 2026Q3 profit coinciding with an OCF/NI ratio of -0.46 suggests non-cash gains or working capital movements are inflating reported earnings rather than reflecting cash generation. Across most quarters the OCF/NI ratio swung between 0.41 and 2.13, indicating the two measures are driven by different forces and that net income is not a reliable proxy for operating performance. Investors should monitor whether the earnings-to-cash gap narrows as the business stabilizes.

Free Cash Flow Deeply Negative Throughout

Based on reported figures, LAB's free cash flow margin reached -182.2% in 2024Q2 and -174.7% in 2025Q1, with the most recent quarter at -31.8%, showing sustained cash consumption relative to revenue even as the burn rate moderated.

Free cash flow was negative in every quarter presented, and the margin compression toward -31.8% in 2026Q3 appears to reflect a shrinking revenue base more than a structural turn in cash generation. The 2026Q2 FCF deficit of -$57.8M shows the burn remained material relative to the company's scale. Without a sustained run of positive FCF, the business appears dependent on existing balance sheet resources, which warrants further investigation.

Volatile Capex Raises Maintenance Questions

As reported in the cash flow statements, LAB's capital expenditures ranged from zero to $5.1M per quarter, with CapEx-to-revenue reaching 25.0% in 2025Q1 before falling to 2.0% in 2025Q4, suggesting spending is discretionary and uneven rather than steady.

The sharp decline in capex from 2025Q1 to 2025Q4 may reflect deliberate spending restraint rather than a completed build-out, so recent low figures may not represent a sustainable maintenance baseline. Depreciation and amortization of $1.4M to $5.6M per quarter indicates the installed asset base requires some ongoing reinvestment. Investors should monitor whether capex stays suppressed for an extended period, as that could defer necessary asset replacement.

Working Capital Swings Dominate Quarterly Cash

According to the reported figures, LAB's working capital changes ranged from -$54.9M in 2026Q1 to +$8.7M in 2024Q4, and these movements appear to account for a large share of quarterly operating cash variance.

The 2026Q1 working capital outflow of $54.9M coincided with a -$46.6M operating cash flow quarter, indicating balance sheet timing rather than core operating losses may have driven much of that shortfall. The reversal to a +$4.9M inflow in 2026Q3 suggests these swings are substantial and difficult to forecast from the data alone. Investors should monitor receivables, inventory, and payables trends to determine whether the pattern reflects timing noise or a recurring drain.

Acquisition Inflow Unexplained by Reported Data

Based on the reported figures, LAB recorded a net acquisition-related inflow of $363.2M in 2026Q1 alongside no dividend payments and only minor buybacks, suggesting capital deployment has been limited during the period.

The $363.2M net acquisition figure in 2026Q1 is unusually large relative to the company's cash flow scale, and the supplied data does not explain its source, so it warrants further investigation. Dividends were nil throughout and buybacks were small or absent, which is consistent with a company preserving cash rather than returning it. Whether this inflow materially strengthens liquidity cannot be determined from the cash flow data alone.

Cash Burn Narrative May Overstate Deterioration

As reported in the cash flow statements, LAB's operating cash outflow narrowed from -$56.9M in 2026Q2 to -$6.2M in 2026Q3, and the bear case may rest on a single quarter's working capital reversal rather than a durable trend.

The 2026Q3 improvement was driven substantially by a +$4.9M working capital inflow and falling SG&A, so bears may argue this is non-recurring rather than evidence of a sustained turn. Conversely, the cumulative FCF deficit across the ten quarters and the absence of any disclosed dividends or buybacks limit the cash-generation case, and the cash flow data alone does not establish whether the recent narrowing will hold.

LAB — Frequently Asked Questions

Quick answers to the most common questions about buying LAB stock.

How much cash does Standard BioTools Inc. (LAB) generate from operations?

Standard BioTools Inc. (LAB) generated $-74.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Standard BioTools Inc.'s free cash flow?

Standard BioTools Inc. (LAB) reported negative free cash flow of $82.7M in 2025, indicating capital requirements exceeded cash from operations.

What is Standard BioTools Inc.'s capital expenditure (CapEx)?

Standard BioTools Inc. (LAB) spent $8.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.